α-Synuclein Levels in Blood Plasma from LRRK2 Mutation Carriers

Ana Gorostidi, Alberto Bergareche, Javier Ruiz-Martínez, José F. Martí-Massó, María Cruz, Shiji Varghese, Mohamed M. Qureshi, Fatimah Alzahmi, Abdulmonem Al-Hayani, Adolfo López de Munáin, Omar Ali El-Agnaf

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The diagnosis of Parkinson's disease (PD) remains primarily a clinical issue, based mainly on phenotypic patterns. The identification of biomarkers capable of permitting the preclinical detection of PD is critically needed. α-Synuclein is a key protein in PD, with missense and multiplication mutations in the gene encoding α-synuclein (SNCA) having been reported in familial cases of PD, and accumulation of the protein identified in Lewy bodies (LBs) and Lewy neurites (LNs) in affected brain regions. With the objective of validating the use of α-synuclein as a clinical or progressive biomarker in an accessible tissue, we used an enzyme-linked immunosorbent assay (ELISA) to measure α-synuclein levels in the peripheral blood plasma of idiopathic PD and LRRK2 mutation carrier patients and compared our findings with healthy control subjects. Compared to healthy controls, we found a significant decrease in plasma total α-synuclein levels in idiopathic PD (iPD) patients (n = 134, p = 0.010). However, the reduction was less significant in patients who were LRRK2 mutation carriers (n = 32, p = 0.133). This lack of significance could be due to the small number of individuals employed in this group. No predictive value of total α-synuclein in the diagnosis of PD was found in a receiver operating characteristic (ROC) curve analysis. Although this is a pilot study requiring corroboration on a larger cohort of patients, our results highlight the possible use of plasma α-synuclein as a biomarker for PD.

Original languageEnglish
Article numbere52312
JournalPLoS One
Volume7
Issue number12
DOIs
Publication statusPublished - 27 Dec 2012
Externally publishedYes

Fingerprint

Synucleins
Parkinson disease
blood plasma
Parkinson Disease
Blood
mutation
Plasmas
Mutation
Biomarkers
biomarkers
Lewy Bodies
Immunosorbents
Gene encoding
neurites
Neurites
Missense Mutation
ROC Curve
Assays
Brain
Healthy Volunteers

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Gorostidi, A., Bergareche, A., Ruiz-Martínez, J., Martí-Massó, J. F., Cruz, M., Varghese, S., ... Ali El-Agnaf, O. (2012). α-Synuclein Levels in Blood Plasma from LRRK2 Mutation Carriers. PLoS One, 7(12), [e52312]. https://doi.org/10.1371/journal.pone.0052312

α-Synuclein Levels in Blood Plasma from LRRK2 Mutation Carriers. / Gorostidi, Ana; Bergareche, Alberto; Ruiz-Martínez, Javier; Martí-Massó, José F.; Cruz, María; Varghese, Shiji; Qureshi, Mohamed M.; Alzahmi, Fatimah; Al-Hayani, Abdulmonem; de Munáin, Adolfo López; Ali El-Agnaf, Omar.

In: PLoS One, Vol. 7, No. 12, e52312, 27.12.2012.

Research output: Contribution to journalArticle

Gorostidi, A, Bergareche, A, Ruiz-Martínez, J, Martí-Massó, JF, Cruz, M, Varghese, S, Qureshi, MM, Alzahmi, F, Al-Hayani, A, de Munáin, AL & Ali El-Agnaf, O 2012, 'α-Synuclein Levels in Blood Plasma from LRRK2 Mutation Carriers', PLoS One, vol. 7, no. 12, e52312. https://doi.org/10.1371/journal.pone.0052312
Gorostidi A, Bergareche A, Ruiz-Martínez J, Martí-Massó JF, Cruz M, Varghese S et al. α-Synuclein Levels in Blood Plasma from LRRK2 Mutation Carriers. PLoS One. 2012 Dec 27;7(12). e52312. https://doi.org/10.1371/journal.pone.0052312
Gorostidi, Ana ; Bergareche, Alberto ; Ruiz-Martínez, Javier ; Martí-Massó, José F. ; Cruz, María ; Varghese, Shiji ; Qureshi, Mohamed M. ; Alzahmi, Fatimah ; Al-Hayani, Abdulmonem ; de Munáin, Adolfo López ; Ali El-Agnaf, Omar. / α-Synuclein Levels in Blood Plasma from LRRK2 Mutation Carriers. In: PLoS One. 2012 ; Vol. 7, No. 12.
@article{ae105f379a1641938e5aa44a644fc60e,
title = "α-Synuclein Levels in Blood Plasma from LRRK2 Mutation Carriers",
abstract = "The diagnosis of Parkinson's disease (PD) remains primarily a clinical issue, based mainly on phenotypic patterns. The identification of biomarkers capable of permitting the preclinical detection of PD is critically needed. α-Synuclein is a key protein in PD, with missense and multiplication mutations in the gene encoding α-synuclein (SNCA) having been reported in familial cases of PD, and accumulation of the protein identified in Lewy bodies (LBs) and Lewy neurites (LNs) in affected brain regions. With the objective of validating the use of α-synuclein as a clinical or progressive biomarker in an accessible tissue, we used an enzyme-linked immunosorbent assay (ELISA) to measure α-synuclein levels in the peripheral blood plasma of idiopathic PD and LRRK2 mutation carrier patients and compared our findings with healthy control subjects. Compared to healthy controls, we found a significant decrease in plasma total α-synuclein levels in idiopathic PD (iPD) patients (n = 134, p = 0.010). However, the reduction was less significant in patients who were LRRK2 mutation carriers (n = 32, p = 0.133). This lack of significance could be due to the small number of individuals employed in this group. No predictive value of total α-synuclein in the diagnosis of PD was found in a receiver operating characteristic (ROC) curve analysis. Although this is a pilot study requiring corroboration on a larger cohort of patients, our results highlight the possible use of plasma α-synuclein as a biomarker for PD.",
author = "Ana Gorostidi and Alberto Bergareche and Javier Ruiz-Mart{\'i}nez and Mart{\'i}-Mass{\'o}, {Jos{\'e} F.} and Mar{\'i}a Cruz and Shiji Varghese and Qureshi, {Mohamed M.} and Fatimah Alzahmi and Abdulmonem Al-Hayani and {de Mun{\'a}in}, {Adolfo L{\'o}pez} and {Ali El-Agnaf}, Omar",
year = "2012",
month = "12",
day = "27",
doi = "10.1371/journal.pone.0052312",
language = "English",
volume = "7",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "12",

}

TY - JOUR

T1 - α-Synuclein Levels in Blood Plasma from LRRK2 Mutation Carriers

AU - Gorostidi, Ana

AU - Bergareche, Alberto

AU - Ruiz-Martínez, Javier

AU - Martí-Massó, José F.

AU - Cruz, María

AU - Varghese, Shiji

AU - Qureshi, Mohamed M.

AU - Alzahmi, Fatimah

AU - Al-Hayani, Abdulmonem

AU - de Munáin, Adolfo López

AU - Ali El-Agnaf, Omar

PY - 2012/12/27

Y1 - 2012/12/27

N2 - The diagnosis of Parkinson's disease (PD) remains primarily a clinical issue, based mainly on phenotypic patterns. The identification of biomarkers capable of permitting the preclinical detection of PD is critically needed. α-Synuclein is a key protein in PD, with missense and multiplication mutations in the gene encoding α-synuclein (SNCA) having been reported in familial cases of PD, and accumulation of the protein identified in Lewy bodies (LBs) and Lewy neurites (LNs) in affected brain regions. With the objective of validating the use of α-synuclein as a clinical or progressive biomarker in an accessible tissue, we used an enzyme-linked immunosorbent assay (ELISA) to measure α-synuclein levels in the peripheral blood plasma of idiopathic PD and LRRK2 mutation carrier patients and compared our findings with healthy control subjects. Compared to healthy controls, we found a significant decrease in plasma total α-synuclein levels in idiopathic PD (iPD) patients (n = 134, p = 0.010). However, the reduction was less significant in patients who were LRRK2 mutation carriers (n = 32, p = 0.133). This lack of significance could be due to the small number of individuals employed in this group. No predictive value of total α-synuclein in the diagnosis of PD was found in a receiver operating characteristic (ROC) curve analysis. Although this is a pilot study requiring corroboration on a larger cohort of patients, our results highlight the possible use of plasma α-synuclein as a biomarker for PD.

AB - The diagnosis of Parkinson's disease (PD) remains primarily a clinical issue, based mainly on phenotypic patterns. The identification of biomarkers capable of permitting the preclinical detection of PD is critically needed. α-Synuclein is a key protein in PD, with missense and multiplication mutations in the gene encoding α-synuclein (SNCA) having been reported in familial cases of PD, and accumulation of the protein identified in Lewy bodies (LBs) and Lewy neurites (LNs) in affected brain regions. With the objective of validating the use of α-synuclein as a clinical or progressive biomarker in an accessible tissue, we used an enzyme-linked immunosorbent assay (ELISA) to measure α-synuclein levels in the peripheral blood plasma of idiopathic PD and LRRK2 mutation carrier patients and compared our findings with healthy control subjects. Compared to healthy controls, we found a significant decrease in plasma total α-synuclein levels in idiopathic PD (iPD) patients (n = 134, p = 0.010). However, the reduction was less significant in patients who were LRRK2 mutation carriers (n = 32, p = 0.133). This lack of significance could be due to the small number of individuals employed in this group. No predictive value of total α-synuclein in the diagnosis of PD was found in a receiver operating characteristic (ROC) curve analysis. Although this is a pilot study requiring corroboration on a larger cohort of patients, our results highlight the possible use of plasma α-synuclein as a biomarker for PD.

UR - http://www.scopus.com/inward/record.url?scp=84871664988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871664988&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0052312

DO - 10.1371/journal.pone.0052312

M3 - Article

VL - 7

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 12

M1 - e52312

ER -